Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00872079 · ClinicalTrials.gov registry record · NA

Personalized Warfarin Dosing by Genomics and Computational Intelligence

A NA study, sponsored by US Department of Veterans Affairs.

Terminated
Registry status
NA
Development phase
175
Enrollment target

NCT00872079: Clinical Trial NA study, sponsored by US Department of Veterans Affairs.

NCT00872079 is a NA study that was terminated before completion, run by US Department of Veterans Affairs. The registered enrollment target is 175 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00872079, a NA study, was terminated before completion, sponsored by US Department of Veterans Affairs.

TERMINATED
Registry status
NA
Development phase
175 participants
Enrollment target

Study Summary

This study will create a computer program that can be used to help dose a drug called warfarin for the prevention of blood clotting. The study will collected specific information about those patients receiving this drug and use that information to create a computer program that will predict the effects of the drug. With this prediction program in place, the investigators can perform a series of "what if I gave this amount of drug" simulations to determine the best dose of drug for that patient. Once the computer programs are developed, the investigators will test the program in patients that actually need this drug. They will also include genetic information into the prediction since it has been shown that this information can affect how well the drug works. Patients will have this genetic information determined during this study.

Primary Outcome

During Aim 2, Determined Patient Genotypes: CYP2C9 and VKORC1.

Interventions

  • DEVICE Genomics

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2008-09
Est. Completion 2011-09
Phase NA
US Department of Veterans Affairs

632 total trials

Why NCT00872079 stopped before completion

NCT00872079 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 1 intervention - of which Genomics is the first listed.

NCT00872079 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00872079 about?

NCT00872079 is a clinical study titled "Personalized Warfarin Dosing by Genomics and Computational Intelligence". This study will create a computer program that can be used to help dose a drug called warfarin for the prevention of blood clotting. The study will collected specific information about those patients receiving this drug and use that information to create a computer program that will predict the effe...

What is the current status of trial NCT00872079?

This trial is currently terminated. It is a NA study. The enrollment target is 175 participants. The study started on 2008-09. Estimated completion is 2011-09.

What interventions are being tested in trial NCT00872079?

The interventions under investigation include: Genomics (DEVICE).

Who is sponsoring clinical trial NCT00872079?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00872079's enrollment target sits among peer trials

175 610th of 2000 higher than 1,391 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04722341 · 175 participants · NA

    Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

  • NCT05094037 · 175 participants · NA

    Orthotic Treatment of Diabetic Foot Ulcers

  • NCT05165745 · 175 participants · NA

    Stick2PrEP Cisgender Women and Trans Individuals

  • NCT05312255 · 175 participants · NA

    Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00872079, the US trial registry maintained by the National Library of Medicine. NCT00872079 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.